Custom‐Made Ceria Nanoparticles Show a Neuroprotective Effect by Modulating Phenotypic Polarization of the Microglia

Zeng, Feng; Wu, Yingwei; Li, Xinwei; Ge, Xiaojiao; Guo, Qinghua; Lou, Xiaobing; Cao, Ziping; Hu, Bingwen; Long, Nicholas J.; Mao, Ying; Liu, Cong

doi:10.1002/anie.201802309

Cited by 149 publications

(117 citation statements)

References 29 publications

Supporting

Mentioning

116

Contrasting

Order By: Relevance

Section: Nanocatalytic Medicine For Nontumoral Therapiesmentioning

confidence: 93%

“…Recent immunological evidences also indicated that CeO 2 nanoparticles can shift the balance of microglial activation from a proinflammatory M1‐phenotype to an anti‐inflammatory M2‐phenotype by scavenging ROS and blocking the proinflammatory signaling (Figure b), further demonstrating that such an inorganic nanozyme is competent for future clinical brain treatment. In addition to CeO 2 , Fe 3 O 4 nanoparticles, GO quantum dots,141b and melanin nanoparticles (Figure c) have also been applied in nanocatalytic brain disease therapies by ROS depletion in pathological regions.…”

Section: Nanocatalytic Medicine For Nontumoral Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Nanocatalytic Medicine

2019

View full text Add to dashboard Cite

Catalysis and medicine are often considered as two independent research fields with their own respective scientific phenomena. Promoted by recent advances in nanochemistry, large numbers of nanocatalysts, such as nanozymes, photocatalysts, and electrocatalysts, have been applied in vivo to initiate catalytic reactions and modulate biological microenvironments for generating therapeutic effects. The rapid growth of research in biomedical applications of nanocatalysts has led to the concept of “nanocatalytic medicine,” which is expected to promote the further advance of such a subdiscipline in nanomedicine. The high efficiency and selectivity of catalysis that chemists strived to achieve in the past century can be ingeniously translated into high efficacy and mitigated side effects in theranostics by using “nanocatalytic medicine” to steer catalytic reactions for optimized therapeutic outcomes. Here, the rationale behind the construction of nanocatalytic medicine is eludicated based on the essential reaction factors of catalytic reactions (catalysts, energy input, and reactant). Recent advances in this burgeoning field are then comprehensively presented and the mechanisms by which catalytic nanosystems are conferred with theranostic functions are discussed in detail. It is believed that such an emerging catalytic therapeutic modality will play a more important role in the field of nanomedicine.

show abstract

Section: Nanocatalytic Medicine For Nontumoral Therapiesmentioning

confidence: 93%

Section: Nanocatalytic Medicine For Nontumoral Therapiesmentioning

confidence: 99%

Nanocatalytic Medicine

2019

View full text Add to dashboard Cite

show abstract

“…15 Recent studies demonstrating the neuroprotective and cardioprotective roles of CeO 2 nanoparticles have been correlated with its antioxidative and redox-modulatory activities. 16,17 On the other hand, nanoceria have been found to produce significant oxidative stress in human bronchoalveolar carcinoma and 18 human hepatocellular carcinoma. 19 In the case of lung adenocarcinoma (A549) cells, CeO 2 increases the production of ROS which leads to a decrease in the antioxidant level of cells and apoptotic cell death.…”

Section: ■ Introductionmentioning

confidence: 99%

Pro-Oxidant Therapeutic Activities of Cerium Oxide Nanoparticles in Colorectal Carcinoma Cells

et al. 2020

View full text Add to dashboard Cite

Given that basal levels of reactive oxygen species (ROS) are higher in cancer cells, there is a growing school of thought that endorses pro-oxidants as potential chemotherapeutic agents. Intriguingly, cerium oxide (CeO 2 ) nanoparticles can manifest either anti-or pro-oxidant activity as a function of differential pH of various subcellular localizations. In an acidic pH environment, for example, in extracellular milieu of cancer cells, CeO 2 would function as a pro-oxidant. Based on this concept, the present study is designed to investigate the pro-oxidant activities of CeO 2 in human colorectal carcinoma cell line (HCT 116). For comparison, we have also studied the effect of ceria nanoparticles on human embryonic kidney (HEK 293) cells. Dose-dependent viability of cancerous as well as normal cells has been assessed by treating them independently with CeO 2 nanoparticles of different concentrations (5−100 μg/mL) in the culture media. The half maximal inhibitory concentration (IC 50 ) of nanoceria for HCT 116 is found to be 50.48 μg/mL while that for the HEK 293 cell line is 92.03 μg/mL. To understand the intricate molecular mechanisms of CeO 2 -induced cellular apoptosis, a series of experiments have been conducted. The apoptosis-inducing ability of nanoceria has been investigated by Annexin V-FITC staining, caspase 3/9 analysis, cytochrome c release, intracellular ROS analysis, and mitochondrial membrane potential analysis using flow cytometry. Experimental data suggest that CeO 2 treatment causes DNA fragmentation through enhanced generation of ROS, which ultimately leads to cellular apoptosis through the p53-dependent mitochondrial signaling pathway.

show abstract

“…Nevertheless, endeavors in developing ceria nanoparticles (NPs) as an effective therapeutic agent have demonstrated the promising potential for the treatment of diseases associated with abrupt surges of ROS. [21][22][23][24][25][26][27] Reversible redox switching between Ce 3+ and Ce 4+ ions in ceria NPs enables the NPs to scavenge ROS for a prolonged period. [28][29][30] Moreover, since it was revealed that Ce 3+ ions are more important than Ce 4+ ions in removing ROS and subsequent amelioration of inflammatory diseases, systems to sustain higher Ce 3+ contents in ceria NPs were designed by inserting dopant ions.…”

Section: Introductionmentioning

confidence: 99%